Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9465-9473

  Li, Ping ^a   Wang, Ya Di ^a   Cheng, Jian ^b   Chen, Jun Chen ^c   Ha, Min Wen ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY HOSPITAL   (China)

^c Rongjun Hospital of Hubei Province   (China)

Author keywords

Advanced non small cell lung cancer; BAG 1; Chemotherapy sensitivity; XPD

Indexed keywords

CISPLATIN; NAVELBINE; ANTINEOPLASTIC AGENT; BCL2-ASSOCIATED ATHANOGENE 1 PROTEIN; DNA BINDING PROTEIN; ERCC2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BAG 1 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CODON; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL PREDICTION; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; XPD GENE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSCRIPTION FACTORS; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84952873263     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3672-z     Document Type: Article

References (31)

1. Xie KJ, He HE, Sun AJ, Liu XB, Sun LP, Dong XJ. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Asian Pac J Cancer Prev. 2014;15(6):2591–6.
2. Cortes R, Tarrado-Castellarnau M, Talancon D, Lopez C, Link W, Ruiz D, et al. A novel cyclometallated Pt(II)-ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation. Metallomics. 2014;6(3):622–33.
3. Lima A, Seabra V, Martins S, Coelho A, Araujo A, Medeiros R. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Mol Biol Rep. 2014;41(5):3349–57.
4. Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483–91.
5. Reinmuth N, Meyer A, Hartwigsen D, Schaeper C, Huebner G, Skock-Lober R, et al. Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIb/IV non-small cell lung cancer (NSCLC). Lung Cancer. 2014;83(3):363–8.
6. Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Lung Cancer. 2014;84(1):51–5.
7. Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, et al. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an international randomized phase II study (NAVotrial 01). Clin Lung Cancer. 2014;15(4):258–65.
8. Chen LK, Liang Y, Yang QY, Xu F, Zhou NN, Xu GC, et al. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2012;13(5):1863–7.
9. Du Y, Su T, Zhao L, Tan X, Chang W, Zhang H, et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS One. 2014;9(6), e99843.
10. Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, et al. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. Oncol Rep. 2012;27(4):979–86.
11. Liman J, Faida L, Dohm CP, Reed JC, Bahr M, Kermer P. Subcellular distribution affects BAG1 function. Brain Res. 2008;1198:21–6.
12. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 1995;80(2):279–84.
13. Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH. Combined analysis of mrna expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res. 2012;31:25.
14. Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, et al. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8(8), e72251.
15. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540–6.
16. Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, et al. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for chinese non-small cell lung cancer patients. PLoS One. 2012;7(3), e33200.
17. Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15(3):159–66.
18. Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 2014;35(4):2905–21.
19. Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a chinese population. Clin Cancer Res. 2009;15(11):3889–95.
20. The Helsinki Declaration of the World Medical Association (WMA). Ethical principles of medical research involving human subjects. Pol Merkur Lekarski. 2014;36(215):298–301.
21. Mor V, Laliberte L, Morris JN, Wiemann M. The karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
23. Liu H, Liang Y, Li Y, Li Y, Wang J, Wu H, et al. Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis. Cancer Biol Ther. 2010;9(10):832–40.
24. Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, et al. BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 2008;29(4):849–57.
25. Zhan P, Wang Q, Wei SZ, Wang J, Qian Q, Yu LK, et al. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case–control studies. J Thorac Oncol. 2010;5(9):1337–45.
26. Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, et al. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects. Breast Cancer Res Treat. 2010;124(1):229–35.
27. Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, et al. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer. 2013;133(4):1016–22.
28. Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011;12(12):1641–52.
29. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40(10):1166–74.
30. Li J, Das K, Fu G, Li R, Wu R. The Bayesian lasso for genome-wide association studies. Bioinformatics. 2011;27(4):516–23.
31. Hoggart CJ, Whittaker JC, De Iorio M, Balding DJ. Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. PLoS Genet. 2008;4(7), e1000130.